New pill shows promise in early trial for Hard-to-Treat cancers
NCT ID NCT05287399
First seen Jan 08, 2026 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. ASC61 works by blocking a protein called PD-L1, which helps the immune system attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Cancer Associates for Research & Excellence (cCARE)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research & Excellence (cCARE)
Fresno, California, 93720, United States
-
California Cancer Associates for Research & Excellence (cCARE)
San Marcos, California, 92069, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.